FDA Approved Products
1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
SALONPAS
menthol, methyl salicylate
Peak
TOPICAL · PATCH
2008
NDA8/100
SAMSCA
tolvaptan
Peak
Otsuka
ORAL · TABLET
2009
NDA8/100
SAVELLA
milnacipran hydrochloride
Peak
AbbVie
ORAL · TABLET
2009
NDA8/100
SEGLUROMET
ertugliflozin and metformin hydrochloride
Peak
Merck & Co.
ORAL · TABLET
2017
NDA8/100
SERNIVO
betamethasone dipropionate
Peak
TOPICAL · SPRAY
2016
NDA8/100
SILENOR
doxepin hydrochloride
Peak
Currax Pharmaceuticals
ORAL · TABLET
2010
NDA8/100
SIMBRINZA
brinzolamide/brimonidine tartrate
Peak
Alcon
OPHTHALMIC · SUSPENSION/DROPS
2013
NDA8/100
SIRTURO
bedaquiline fumarate
Peak
Enthera Pharmaceuticals
ORAL · TABLET
2012
NDA8/100
SITAVIG
acyclovir
Peak
BUCCAL · TABLET
2013
SMNDA8/100
SIVEXTRO
tedizolid phosphate
Peak
ORAL · TABLET
2014
NDA8/100
SIVEXTRO
tedizolid phosphate
Peak
INTRAVENOUS · POWDER
2014
NDA8/100
SKYLA
levonorgestrel
Peak
Bayer
INTRAUTERINE · SYSTEM
pregnancy for up to 3 years
2013
NDA8/100
STEGLATRO
ertugliflozin
Peak
Merck & Co.
ORAL · TABLET
2017
SMNDA8/100
STEGLUJAN
ertugliflozin and sitagliptin
Peak
Merck & Co.
ORAL · TABLET
2017
SMNDA8/100
STIOLTO RESPIMAT
tiotropium bromide and olodaterol
Peak
Boehringer Ingelheim
INHALATION · SPRAY, METERED
acute deterioration of COPDasthma+2
2015
NDA8/100
SUBOXONE
buprenorphine hydrochloride, naloxone hydrochloride
Peak
Indivior
BUCCAL, SUBLINGUAL · FILM
2010
NDA8/100
SUBSYS
fentanyl
Peak
SUBLINGUAL · SPRAY
2012
NDA8/100
SUPRENZA
phentermine hydrochloride
Peak
ORAL · TABLET, ORALLY DISINTEGRATING
2011
NDA8/100
TEFLARO
ceftaroline fosamil
Peak
AbbVie
INTRAVENOUS · POWDER
2010
NDA8/100
TEKAMLO
aliskiren hemifumarate; amlodipine besylate
Peak
Novartis
ORAL · TABLET
2010
NDA8/100
TEPMETKO
tepotinib hydrochloride
Peak
ORAL · TABLET
2021
NDA8/100
TIGLUTIK KIT
riluzole
Peak
Italfarmaco Research
ORAL · SUSPENSION
2018
SMNDA8/100
TIVICAY
dolutegravir sodium
Peak
GSK
ORAL · TABLET
combination with rilpivirineknown substitutions associated with resistance to either antiretroviral agent+4
2013
NDA8/100
TIVICAY PD
dolutegravir sodium
Peak
GSK
ORAL · TABLET, FOR SUSPENSION
combination with rilpivirineknown substitutions associated with resistance to either antiretroviral agent+4
2020
NDA8/100